Yesterday, drug maker Kite Pharma Inc (NASDAQ:KITE) disclosed the death of a patient who was treated with KTE-C19, the company’s CAR-T blood cancer drug, …
Kite Pharma Inc (NASDAQ:KITE) shares tumbled nearly 13% to $70.99 in Monday’s trading session, after the drug maker announced a grade 5 case …
Kite Pharma Inc (NASDAQ:KITE) reported first quarter 2017 financial results and provided a corporate update for the period ended March 31, 2017. “Kite is …
In the biotech sphere, J.P.
Yesterday, Kite Pharma Inc (NASDAQ:KITE) impressed at the 2017 American Association of Cancer Research annual meeting, presenting an encouraging full six- month data …
Kite Pharma Inc (NASDAQ:KITE) announced that it has completed the rolling submission with theU.S.
Maxim analyst Jason McCarthy is out today with a research note on shares of Kite Pharma Inc (NASDAQ:KITE), after holding a first China focused Healthcare …
Following a KOL discussion of Car-T therapies coupled with this week’s encouraging clinical update on the ZUMA-1 trial in Non-Hodgkin’s lymphoma (LMA), top …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Kite Pharma Inc (NASDAQ:KITE) were two predominant needle-movers yesterday in the volatile biotech market, with Valeant shares …
Kite Pharma Inc (NASDAQ:KITE) announced the pricing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a …
